Log in to save to my catalogue

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_500863

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

About this item

Full title

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

Publisher

Cham: Springer International Publishing

Journal title

CNS drugs, 2017-01, Vol.31 (1), p.33-50

Language

English

Formats

Publication information

Publisher

Cham: Springer International Publishing

More information

Scope and Contents

Contents

Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab shou...

Alternative Titles

Full title

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_500863

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_500863

Other Identifiers

ISSN

1172-7047

E-ISSN

1179-1934

DOI

10.1007/s40263-016-0394-8

How to access this item